21 research outputs found
Revisiting Weyl's calculation of the gravitational pull in Bach's two-body solution
When the mass of one of the two bodies tends to zero, Weyl's definition of
the gravitational force in an axially symmetric, static two-body solution can
be given an invariant formulation in terms of a force four-vector. The norm of
this force is calculated for Bach's two-body solution, that is known to be in
one-to-one correspondence with Schwarzschild's original solution when one of
the two masses l, l' is made to vanish. In the limit when, say, l' goes to
zero, the norm of the force divided by l' and calculated at the position of the
vanishing mass is found to coincide with the norm of the acceleration of a test
body kept at rest in Schwarzschild's field. Both norms happen thus to grow
without limit when the test body (respectively the vanishing mass l') is kept
at rest in a position closer and closer to Schwarzschild's two-surface.Comment: 11 pages, 2 figures. Text to appear in Classical and Quantum Gravit
The Electrostatics of Einstein's Unified Field Theory
When sources are added at their right-hand sides, and g_{(ik)} is a priori
assumed to be the metric, the equations of Einstein's Hermitian theory of
relativity were shown to allow for an exact solution that describes the general
electrostatic field of n point charges. Moreover, the injunction of spherical
symmetry of g_{(ik)} in the infinitesimal neighbourhood of each of the charges
was proved to yield the equilibrium conditions of the n charges in keeping with
ordinary electrostatics. The tensor g_{(ik)}, however, cannot be the metric of
the theory, since it enters neither the eikonal equation nor the equation of
motion of uncharged test particles. A physically correct metric that rules both
the behaviour of wave fronts and of uncharged matter is the one indicated by
H\'ely. In the present paper it is shown how the electrostatic solution
predicts the structure of the n charged particles and their mutual positions of
electrostatic equilibrium when H\'ely's physically correct metric is adopted.Comment: 15 pages. Misprints corrected. To appear in General Relativity and
Gravitatio
The JNK Inhibitor XG-102 Protects against TNBS-Induced Colitis
The c-Jun N-terminal kinase (JNK)-inhibiting peptide D-JNKI-1, syn. XG-102 was tested for its therapeutic potential in acute inflammatory bowel disease (IBD) in mice. Rectal instillation of the chemical irritant trinitrobenzene sulfonic acid (TNBS) provoked a dramatic acute inflammation in the colon of 7–9 weeks old mice. Coincident subcutaneous application of 100 µg/kg XG-102 significantly reduced the loss of body weight, rectal bleeding and diarrhoea. After 72 h, the end of the study, the colon was removed and immuno-histochemically analysed. XG-102 significantly reduced (i) pathological changes such as ulceration or crypt deformation, (ii) immune cell pathology such as infiltration and presence of CD3- and CD68-positive cells, (iii) the production of tumor necrosis factor (TNF)-α in colon tissue cultures from TNBS-treated mice, (iv) expression of Bim, Bax, FasL, p53, and activation of caspase 3, (v) complexation of JNK2 and Bim, and (vi) expression and activation of the JNK substrate and transcription factor c-Jun. A single application of subcutaneous XG-102 was at least as effective or even better depending on the outcome parameter as the daily oral application of sulfasalazine used for treatment of IBD
Determination and correction of aberrations in full field optical coherence tomography using phase gradient autofocus by maximizing the likelihood function
Aberrant ZNF423 impedes B cell differentiation and is linked to adverse outcome of <em>ETV6-RUNX1</em> negative B precursor acute lymphoblastic leukemia.
Differentiation arrest is a hallmark of acute leukemia. Genomic alterations in B cell differentiation factors such as PAX5, IKZF1, and EBF-1 have been identified in more than half of all cases of childhood B precursor acute lymphoblastic leukemia (ALL). Here, we describe a perturbed epigenetic and transcriptional regulation of ZNF423 in ALL as a novel mechanism interfering with B cell differentiation. Hypomethylation of ZNF423 regulatory sequences and BMP2 signaling result in transactivation of ZNF423 alpha and a novel ZNF423 beta-isoform encoding a nucleosome remodeling and histone deacetylase complex-interacting domain. Aberrant ZNF423 inhibits the transactivation of EBF-1 target genes and leads to B cell maturation arrest in vivo. Importantly, ZNF423 expression is associated with poor outcome of ETV6-RUNX1-negative B precursor ALL patients. Our work demonstrates that ALL is more than a genetic disease and that epigenetics may uncover novel mechanisms of disease with prognostic implications
Combined inhibition of receptor tyrosine and p21-activated kinases as a therapeutic strategy in childhood ALL.
Receptor tyrosine kinase (RTK)-dependent signaling has been implicated in the pathogenesis of acute lymphoblastic leukemia (ALL) of childhood. However, the RTK-dependent signaling state and its interpretation with regard to biological behavior are often elusive. To decipher signaling circuits that link RTK activity with biological output in vivo, we established patient-derived xenograft ALL (PDX-ALL) models with dependencies on fms-like tyrosine kinase 3 (FLT3) and platelet-derived growth factor receptor β (PDGFRB), which were interrogated by phosphoproteomics using iTRAQ mass spectrometry. Signaling circuits were determined by receptor type and cellular context with few generic features, among which we identified group I p21-activated kinases (PAKs) as potential therapeutic targets. Growth factor stimulation markedly increased catalytic activities of PAK1 and PAK2. RNA interference (RNAi)-mediated or pharmacological inhibition of PAKs using allosteric or adenosine triphosphate (ATP)-competitive compounds attenuated cell growth and increased apoptosis in vitro. Notably, PAK1- or PAK2-directed RNAi enhanced the antiproliferative effects of the type III RTK and protein kinase C inhibitor midostaurin. Treatment of FLT3- or PDGFRB-dependent ALLs with ATP-competitive PAK inhibitors markedly decreased catalytic activities of both PAK isoforms. In FLT3-driven ALL, this effect was augmented by coadministration of midostaurin resulting in synergistic effects on growth inhibition and apoptosis. Finally, combined treatment of PDX-ALL with the ATP-competitive group I PAK inhibitor FRAX486 and midostaurin in vivo significantly prolonged leukemia progression-free survival compared with midostaurin monotherapy or control. Our study establishes PAKs as potential downstream targets in RTK-dependent ALL of childhood, the inhibition of which might help prevent the selection or acquisition of resistance mutations toward tyrosine kinase inhibitors
High-Throughput Phosphotyrosine Profiling Using SH2 Domains
Protein tyrosine phosphorylation controls many aspects of signaling in multicellular organisms. One of the major consequences of tyrosine phosphorylation is the creation of binding sites for proteins containing Src homology 2 (SH2) domains. To profile the global tyrosine phosphorylation state of the cell, we have developed proteomic binding assays encompassing nearly the full complement ofhuman SH2 domains. Here we provide a global view of SH2 domain binding to cellular proteins based on large-scale far-western analyses. We also use reverse-phase protein arrays to generate comprehensive, quantitative SH2 binding profiles for phosphopeptides, recombinant proteins, and entire proteomes. As an example, we profiled the adhesion-dependent SH2 binding interactions in fibroblasts and identified specific focal adhesion complex proteins whose tyrosine phosphorylation and binding to SH2 domains are modulated by adhesion. These results demonstrate that high-throughput comprehensive SH2 profiling provides valuable mechanistic insights into tyrosine kinase signaling pathways